Nasdaq

Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications

WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring ...
Nasdaq

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of ...

Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST CHESTER, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.
Nature

Structure of α-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores

α-Latrotoxin (LTX) stimulates exhaustive release of neurotransmitters and peptides from neuronal and endocrine cells and is widely used as a tool to study exocytosis 1,2,3,4. LTX represents a family ...